OSE IMMUNO (OSE.PA)

FR0012127173 - Common Stock

6.65  +0.21 (+3.26%)

Fundamental Rating

2

OSE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 80 industry peers in the Biotechnology industry. OSE may be in some trouble as it scores bad on both profitability and health. OSE has a decent growth rate and is not valued too expensively.



1

1. Profitability

1.1 Basic Checks

In the past year OSE has reported negative net income.
In the past year OSE has reported a negative cash flow from operations.
OSE had negative earnings in each of the past 5 years.
OSE had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

OSE's Return On Assets of -28.03% is in line compared to the rest of the industry. OSE outperforms 54.67% of its industry peers.
OSE has a Return On Equity of -100.12%. This is comparable to the rest of the industry: OSE outperforms 41.33% of its industry peers.
Industry RankSector Rank
ROA -28.03%
ROE -100.12%
ROIC N/A
ROA(3y)-21.31%
ROA(5y)-17.25%
ROE(3y)-63.23%
ROE(5y)-44.92%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

OSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

2

2. Health

2.1 Basic Checks

OSE does not have a ROIC to compare to the WACC, probably because it is not profitable.
OSE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for OSE has been increased compared to 5 years ago.
OSE has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.30, we must say that OSE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OSE (-0.30) is comparable to the rest of the industry.
OSE has a Debt/Equity ratio of 1.68. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.68, OSE is doing worse than 65.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.68
Debt/FCF N/A
Altman-Z -0.3
ROIC/WACCN/A
WACC7.69%

2.3 Liquidity

OSE has a Current Ratio of 1.62. This is a normal value and indicates that OSE is financially healthy and should not expect problems in meeting its short term obligations.
OSE has a Current ratio (1.62) which is in line with its industry peers.
OSE has a Quick Ratio of 1.62. This is a normal value and indicates that OSE is financially healthy and should not expect problems in meeting its short term obligations.
OSE has a Quick ratio (1.62) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62

4

3. Growth

3.1 Past

OSE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.67%.
Looking at the last year, OSE shows a very negative growth in Revenue. The Revenue has decreased by -87.83% in the last year.
The Revenue for OSE have been decreasing by -38.07% on average. This is quite bad
EPS 1Y (TTM)-22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.18%
Revenue 1Y (TTM)-87.83%
Revenue growth 3Y-40.23%
Revenue growth 5Y-38.07%
Sales Q2Q%-61.46%

3.2 Future

The Earnings Per Share is expected to grow by 75.64% on average over the next years. This is a very strong growth
OSE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 76.27% yearly.
EPS Next Y174.79%
EPS Next 2Y106.51%
EPS Next 3Y75.64%
EPS Next 5YN/A
Revenue Next Year197.62%
Revenue Next 2Y101%
Revenue Next 3Y76.27%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OSE. In the last year negative earnings were reported.
OSE is valuated cheaply with a Price/Forward Earnings ratio of 7.30.
Based on the Price/Forward Earnings ratio, OSE is valued cheaper than 92.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.69, OSE is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 7.3

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

OSE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
OSE's earnings are expected to grow with 75.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y106.51%
EPS Next 3Y75.64%

0

5. Dividend

5.1 Amount

No dividends for OSE!.
Industry RankSector Rank
Dividend Yield N/A

OSE IMMUNO

EPA:OSE (7/24/2024, 2:41:01 PM)

6.65

+0.21 (+3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap144.66M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.3
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.03%
ROE -100.12%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 1.68
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-22.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y174.79%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-87.83%
Revenue growth 3Y-40.23%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y